The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Standardized methods for the production of high specific-activity zirconium-89
Open accessAbstract
Zirconium-89 is an attractive metallo-radionuclide for use in immunoPET due to the favorable decay characteristics. Standardized methods for the routine production and isolation of high purity and high specific-activity 89Zr using a small cyclotron are reported. Optimized cyclotron conditions reveal high average yields of 1.52 ± 0.11 mCi/μA·h at a proton beam energy of 15 MeV and current of 15 μA using a solid, commercially available 89Y-foil target (0.1 mm, 100% natural abundance). 89Zr was isolated in high radionuclidic and radiochemical purity (>99.99%) as [89Zr]Zr-oxalate by using a solid-phase hydroxamate resin with >99.5% recovery of the radioactivity. The effective specific-activity of 89Zr was found to be in the range 5.28 – 13.43 mCi/μg (470 – 1195 Ci/mmol) of zirconium. New methods for the facile production of [89Zr]Zr-chloride are reported. Radiolabeling studies using the trihydroxamate ligand desferrioxamine B (DFO) gave 100% radiochemical yields in <15 min. at room temperature and in vitro stability measurements confirmed that [89Zr]Zr-DFO is stable with respect to ligand dissociation in human serum for >7 days. Small-animal PET imaging studies have demonstrated that free 89Zr(IV) ions administered as [89Zr]Zr-chloride accumulate in the liver whilst [89Zr]Zr-DFO is excreted rapidly via the kidneys within <20 min. These results have important implication for the analysis of immunoPET imaging of 89Zr-labeled monoclonal antibodies. The detailed methods described can be easily translated to other radiochemistry facilities and will facilitate the use of 89Zr in both basic science and clinical investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficient production of high specific activity 64Cu using a biomedical cyclotron
McCarthy, D. W., Shefer, R. E., Klinkowstein, R. E., Bass, L. A., Margeneau, W. H., Cutler, C. S., Anderson, C. J., & Welch, M. J. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00157-6 · Cited by 533
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 330
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
Boswell, C. A., & Brechbiel, M. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.04.001 · Cited by 241
Perk, L. R., Visser, G. W. M., Vosjan, M. J. W. D., van Walsum, M., Tijink, B. M., Leemans, C. R., & van Dongen, G. A. M. S. (2005) · PubMed · Cited by 205
Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
Aerts, H. J. W. L., Dubois, L., Perk, L., Vermaelen, P., van Dongen, G. A. M. S., Wouters, B. G., & Lambin, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054312 · Cited by 194
Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges
Nayak, T. K., & Brechbiel, M. W. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800299f · Cited by 193
Routine Quality Control of Clinical Nuclear Medicine Instrumentation: A Brief Review
ZANZONICO, P. B. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.050203 · Cited by 189
Antibodies and Antimatter: The Resurgence of Immuno-PET
Wu, A. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056887 · Cited by 184
Performance Measurement of the microPET Focus 120 Scanner
Kim, J. S., Lee, J. S., Im, K. C., Kim, S. J., Kim, S.-Y., Lee, D. S., & Moon, D. H. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.040550 · Cited by 180
Cited by
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Dai, Y., Yang, Z., Cheng, S., Wang, Z., Zhang, R., Zhu, G., Wang, Z., Yung, B. C., Tian, R., Jacobson, O., et al. (2018) · Advanced Materials · doi:10.1002/adma.201704877 · Cited by 409
Pandit-Taskar, N., Postow, M. A., Hellmann, M. D., Harding, J. J., Barker, C. A., O’Donoghue, J. A., Ziolkowska, M., Ruan, S., Lyashchenko, S. K., Tsai, F., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229781 · Cited by 257
Self-citationPriem, B., van Leent, M. M. T., Teunissen, A. J. P., Sofias, A. M., Mourits, V. P., Willemsen, L., Klein, E. D., Oosterwijk, R. S., Meerwaldt, A. E., Munitz, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.059 · Cited by 222
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128
Metadata
- Authors
- Holland, J. P., Sheh, Y., & Lewis, J. S.
- Venue
- Nuclear Medicine and Biology
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 36
- Issue
- 7
- Pages
- 729-739
- ISSN
- 0969-8051 (ISSN-L)
- OpenAlex
- W2150228337
- Cited by
- 408
- References
- 14
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Standardized methods for the production of high specific-activity zirconium-89. https://app.cochat.ai/papers/10.1016/j.nucmedbio.2009.05.007
- The paper
- Holland, J. P., Sheh, Y., & Lewis, J. S. (2009). Standardized methods for the production of high specific-activity zirconium-89. Nuclear Medicine and Biology. https://doi.org/10.1016/j.nucmedbio.2009.05.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
